{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:13:49Z","timestamp":1778793229054,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>ADO2 is a heritable osteosclerotic disorder that usually results from heterozygous missense dominant negative mutations in the chloride channel 7 gene (CLCN7). ADO2 is characterized by a wide range of features and severity, including multiple fractures, impaired vision due to secondary bony overgrowth and\/or the lack of the optical canal enlargement with growth, and osteonecrosis\/osteomyelitis. The disease is presently incurable, although anecdotal evidence suggests that calcitriol and interferon gamma-1b (IFN-G) may have some beneficial effects. To identify the role of these drugs for the treatment of ADO2, we utilized a knock-in (G213R mutation in Clcn7) ADO2 mouse model that resembles the human disease. Six-week-old ADO2 heterozygous mice were administered vehicle (PBS) or calcitriol or IFN-G 5 times per week for 8 weeks. We determined bone phenotypes using DXA and \u03bcCT, and analyzed serum biochemistry and bone resorption markers. ADO2 mice treated with all doses of IFN-G significantly (p&amp;lt;0.05) attenuated the increase of whole body aBMD and distal femur BV\/TV gain in both male and female compared to the vehicle group. In contrast, mice treated with low and medium doses of calcitriol showed a trend of higher aBMD and BV\/TV whereas high dose calcitriol significantly (p&amp;lt;0.05) increased bone mass compared to the vehicle group. The calcium and phosphorus levels did not differ between vehicle and IFN-G or calcitriol treated mice; however, we detected significantly (p&amp;lt;0.05) elevated levels of CTX\/TRAP5b ratio in IFN-G treated mice. Our findings indicate that while IFN-G at all doses substantially improved the osteopetrotic phenotypes in ADO2 heterozygous mice, calcitriol treatment at any dose did not improve the phenotype and at high dose further increased bone mass. Thus, use of high dose calcitriol therapy in ADO2 patients merits serious reconsideration. Importantly, our data support the prospect of a clinical trial of IFN-G in ADO2 patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.2545","type":"journal-article","created":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T22:31:33Z","timestamp":1430865093000},"page":"2005-2013","source":"Crossref","is-referenced-by-count":25,"title":["Interferon Gamma, but not Calcitriol Improves the Osteopetrotic Phenotypes in ADO2 Mice"],"prefix":"10.1093","volume":"30","author":[{"given":"Imranul","family":"Alam","sequence":"first","affiliation":[{"name":"MedicineIndiana University School of MedicineINUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amie K.","family":"Gray","sequence":"additional","affiliation":[{"name":"MedicineIndiana University School of MedicineINUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dena","family":"Acton","sequence":"additional","affiliation":[{"name":"MedicineIndiana University School of MedicineINUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita L.","family":"Gerard-O'Riley","sequence":"additional","affiliation":[{"name":"MedicineIndiana University School of MedicineINUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin M.","family":"Reilly","sequence":"additional","affiliation":[{"name":"MedicineIndiana University School of MedicineINUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Econs","sequence":"additional","affiliation":[{"name":"Medical and Molecular GeneticsIndiana University School of MedicineINUSA"},{"name":"MedicineIndiana University School of MedicineINUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"key":"2024020319012352100_jbmr2545-bib-0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00003086-199309000-00006","article-title":"Autosomal dominant osteopetrosis","volume":"294","author":"Bollerslev","year":"1993","journal-title":"Clin Orthop Relat Res."},{"key":"2024020319012352100_jbmr2545-bib-0002","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1093\/hmg\/10.25.2861","article-title":"Albers-Sch\u00f6nberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene","volume":"10","author":"Cleiren","year":"2001","journal-title":"Hum Mol Genet."},{"key":"2024020319012352100_jbmr2545-bib-0003","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1399-0004.1987.tb02774.x","article-title":"A genetic and epidemiological study","volume":"31","author":"Bollerslev","year":"1987","journal-title":"Clin Genet."},{"key":"2024020319012352100_jbmr2545-bib-0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jmg.2005.036673","article-title":"Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment","volume":"43","author":"Del Fattore","year":"2006","journal-title":"J Med Genet"},{"key":"2024020319012352100_jbmr2545-bib-0005","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1210\/jc.2006-1986","article-title":"Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation","volume":"92","author":"Waguespack","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"7)","key":"2024020319012352100_jbmr2545-bib-0006","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM198402163100701","article-title":"Treatment of congenital osteopetrosis with high-dose calcitriol","volume":"310","author":"Key","year":"1984","journal-title":"N Engl J Med."},{"issue":"1)","key":"2024020319012352100_jbmr2545-bib-0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3476(05)82557-0","article-title":"Recombinant human interferon gamma therapy for osteopetrosis","volume":"121","author":"Key","year":"1992","journal-title":"J Pediatr."},{"issue":"24)","key":"2024020319012352100_jbmr2545-bib-0008","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM199506153322402","article-title":"Long-term treatment of osteopetrosis with recombinant human interferon gamma","volume":"332","author":"Key","year":"1995","journal-title":"N Engl J Med."},{"key":"2024020319012352100_jbmr2545-bib-0009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bone.2013.10.021","article-title":"Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models","author":"Alam","year":"2014","journal-title":"Bone."},{"issue":"10)","key":"2024020319012352100_jbmr2545-bib-0010","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/BF02073378","article-title":"Failure of calcitriol treatment in a patient with malignant osteopetrosis","volume":"152","author":"van Lie Peters","year":"1993","journal-title":"Eur J Pediatr."},{"issue":"7)","key":"2024020319012352100_jbmr2545-bib-0011","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1089\/107999000414826","article-title":"Key LL Jr. IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production","volume":"20","author":"Madyastha","year":"2000","journal-title":"J Interferon Cytokine Res."},{"issue":"3)","key":"2024020319012352100_jbmr2545-bib-0012","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jcb.10074","article-title":"Characterization of interferon gamma receptors on osteoclasts: effect of interferon gamma on osteoclastic superoxide generation","volume":"84","author":"Yang","year":"2002","journal-title":"J Cell Biochem."},{"issue":"7)","key":"2024020319012352100_jbmr2545-bib-0013","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/jbmr.350","article-title":"Interferon-\u03b3 plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice","volume":"26","author":"Duque","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"4)","key":"2024020319012352100_jbmr2545-bib-0014","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jbmr.5650040418","article-title":"Interferon gamma and calcitonin induce differential changes in cellular kinetics and morphology of osteoclasts in cultured neonatal mouse calvaria","volume":"4","author":"Klaushofer","year":"1989","journal-title":"J Bone Miner Res."},{"issue":"3)","key":"2024020319012352100_jbmr2545-bib-0015","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.bbrc.2004.12.005","article-title":"RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells","volume":"328","author":"Pang","year":"2005","journal-title":"Biochem Biophys Res Commun."},{"issue":"1)","key":"2024020319012352100_jbmr2545-bib-0016","first-page":"351","volume":"80","author":"Kamolmatyakul","year":"2001","journal-title":"Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J Dent Res."},{"issue":"6812)","key":"2024020319012352100_jbmr2545-bib-0017","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/35046102","article-title":"T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma","volume":"408","author":"Takayanagi","year":"2000","journal-title":"Nature."},{"issue":"3)","key":"2024020319012352100_jbmr2545-bib-0018","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1006\/bbrc.2000.3577","article-title":"Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis","volume":"276","author":"Fox","year":"2000","journal-title":"Biochem Biophys Res Commun."},{"issue":"1)","key":"2024020319012352100_jbmr2545-bib-0019","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1089\/jir.2011.0019","article-title":"Molecular mechanisms of the biphasic effects of interferon-\u03b3 on osteoclastogenesis","volume":"32","author":"Cheng","year":"2012","journal-title":"J Interferon Cytokine Res."},{"issue":"11)","key":"2024020319012352100_jbmr2545-bib-0020","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.4049\/jimmunol.0900072","article-title":"Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors","volume":"183","author":"Ji","year":"2009","journal-title":"J Immunol."},{"issue":"1)","key":"2024020319012352100_jbmr2545-bib-0021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00063030-199707010-00004","article-title":"Key LL Jr. Osteopetrosis: pathogenesis and rationale for the use of interferon-\u03b3-1b","volume":"7","author":"Shankar","year":"1997","journal-title":"BioDrugs."},{"issue":"5)","key":"2024020319012352100_jbmr2545-bib-0022","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jbmr.5650110515","article-title":"Key LL Jr. Osteoclastic superoxide production and bone resorption: stimulation and inhibition by modulators of NADPH oxidase","volume":"11","author":"Darden","year":"1996","journal-title":"J Bone Miner Res."},{"key":"2024020319012352100_jbmr2545-bib-0023","first-page":"384","article-title":"Combination macrophage-colony stimulating factor and interferon-gamma administration ameliorates the osteopetrotic condition in microphthalmic (mi\/mi) mice","author":"Rodriguiz","year":"1993","journal-title":"Pediatr Res."},{"issue":"1)","key":"2024020319012352100_jbmr2545-bib-0024","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1172\/JCI30074","article-title":"IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation","volume":"117","author":"Gao","year":"2007","journal-title":"J Clin Invest."},{"issue":"5)","key":"2024020319012352100_jbmr2545-bib-0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5483\/BMBRep.2012.45.5.281","article-title":"Effect of interferon-\u03b3 on the fusion of mononuclear osteoclasts into bone-resorbing osteoclasts","volume":"45","author":"Kim","year":"2012","journal-title":"BMB Rep."},{"issue":"3)","key":"2024020319012352100_jbmr2545-bib-0026","first-page":"201","article-title":"Carnes DL Jr. A link between calcitriol and bone resorption","volume":"3","author":"Key","year":"1988","journal-title":"Bone Miner."},{"issue":"2)","key":"2024020319012352100_jbmr2545-bib-0027","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1172\/JCI113089","article-title":"1,25\u2013Dihydroxyvitamin D3 stimulates rat osteoblastic cells to release a soluble factor that increases osteoclastic bone resorption","volume":"80","author":"McSheehy","year":"1987","journal-title":"J Clin Invest"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2545","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/11\/2005\/56567069\/jbmr2545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/11\/2005\/56567069\/jbmr2545.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:54:20Z","timestamp":1710341660000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/30\/11\/2005-2013\/7599109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,5,5]]},"published-print":{"date-parts":[[2015,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2545","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,11,1]]},"published":{"date-parts":[[2015,5,5]]}}}